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OBJECTIVES The study was undertaken to develop a coronary microvascular spasm model in pigs by
repeated epicardial coronary artery endothelial injury.
BACKGROUND The pathophysiologic mechanisms responsible for coronary microvascular spasm remain
unclear, in large part because a suitable animal model has yet to be found.
METHODS Balloon endothelial denudation was done just distal to the site of an implanted Doppler
flowmeter in the left anterior descending coronary artery (LAD) every two weeks for a total
of four times. Changes in LAD blood flow by intracoronary administration of vasoactive
agents were assessed before each denudation.
RESULTS In the epicardial LAD endothelial denudation pigs, decreases in LAD blood flow caused by
acetylcholine were augmented. Before denudation, it was 215 6 4%, and at week 8 (i.e., two
weeks after the fourth denudation) it was 2100% (i.e., zero flow [p , 0.01]). The LAD flow
changes in response to 5-hydroxytryptamine (5-HT) changed from an increase to a decrease,
accompanied by medial thickening of microvessels in the LAD perfusion area. These flow
responses were observed without significant changes in LAD diameter. In contrast, the LAD
blood flow responses to acetylcholine and 5-HT did not change throughout the experiment
in pigs given aspirin and a thromboxane A2 (TXA2) synthase inhibitor orally.
CONCLUSIONS This microvascular spasm model indicates that hypersensitivity to vasoactive substances in the
microvascular beds as well as microvascular remodeling are brought about partly through
TXA2. This model should be useful for examining the pathophysiology and treatment of
microvascular angina. (J Am Coll Cardiol 2001;37:308–15) © 2001 by the American
College of Cardiology
Despite many studies, there is still no consensus on the
pathophysiology of coronary microvascular angina or spasm
(1–4). Therefore, not only the pathogenesis of coronary
microvascular angina but also its prevention and treatment
remain important clinical problems. One reason for the lack
of progress is that a microvascular angina model is not
available.
It has been reported that hypertension (5), hypercholes-
terolemia (6) and diabetes mellitus (7) induce epicardial
coronary artery endothelial damage, which is likely to occur
repeatedly over the course of a lifetime. To mimic this
process, we performed repeated epicardial coronary artery
endothelial injury every two weeks, leading to the remod-
eling of the injured epicardial vessel as well as changes in its
vascular reactivity (8). In this procedure, platelet activation
may occur occasionally at the damaged endothelial site (9),
which may produce potent vasoconstrictive substances such
as thromboxane A2 (TXA2) and 5-hydroxytryptamine (5-
HT) (10). It is possible that these substances might induce
downstream microvascular spasm and remodeling. In the
present study, we tried to develop a new coronary micro-
vascular spasm model in the pig by producing endothelial
injury repeatedly in the upstream epicardial coronary artery.
METHODS
After general anesthesia with sodium thiopental (2 mg/kg,
IV) and 1% halothane, under sterile conditions and with
artificial ventilation, pigs (22 6 0.8 kg, n 5 36) underwent
a left thoracotomy at the fourth intercostal space. We
implanted an ultrasonic transit-time flowmeter (Transonic
T201D, Transonic System, New York) around the epicar-
dial left anterior descending coronary artery (LAD). The
chest was closed in layers, and analgesia was provided after
surgery with 0.2 mg IM bupurenorphine (Otsuka, Osaka,
Japan). Prophylactic 1 g IM flomoxef sodium (Shionogi,
Osaka, Japan) and 600 mg IM clindamycin phosphate
(Nihon-Upjhon, Tokyo, Japan) were administered for five
days after surgery.
Experiments were initiated two weeks after surgery. At
first, we made control recordings of the LAD diameter
using a coronary angiogram, the LAD blood flow with a
flowmeter, electrocardiograms (ECGs) from limb (III, aVF)
and precordial lead (V5), and aortic blood pressure via the
8F sheath introducer (Termo, Tokyo, Japan) inserted from
the carotid artery using a pressure transducer (AP641G,
Nihon Koden). We calculated the mean aortic pressure-rate
product (mm Hg/min) and LAD vascular resistance (mean
aortic pressure/mean LAD blood flow; mm Hg/ml/min).
The ECG ST-segment shifts were determined at a point
80 ms after the QRS onset. Next, these measurements were
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repeated after administration of vasoactive substances into
the left coronary artery (LCA) at doses similar to those
reported previously (11,12) [acetylcholine 0.05 mg/kg (Ovi-
sot, Daiichi, Tokyo, Japan), 5-HT 1 mg/kg (Wako Pure
Chemical, Tokyo, Japan), isosorbide dinitrate (ISDN)
10 mg/kg (Eisai, Tokyo, Japan), and adenosine 10 mg/kg
(Sigma Chemical, St. Louis, Missouri)].
We also tested different doses of acetylcholine (0.01 and
0.5 mg/kg) and 5-HT (0.1 and 10 mg/kg). When larger
doses of these drugs were administered, the epicardial
conduit artery showed coronary vasoconstriction [% diam-
eter reduction after 0.5 mg/kg acetylcholine (n 5 5) from
1 6 1% (week 0) to 12 6 5% with severe delay of contrast
medium (week 8, p , 0.05); after 10 mg/kg 5-HT (n 5 5)
from 7 6 4% (week 0) to 92 6 8% (week 8, p , 0.01)], and
a greater flow reduction occurred earlier [% flow reduction
after 0.5 mg/kg acetylcholine (n 5 5) from 232 6 5% (week
0) to 2100% (week 4, p , 0.01); after 10 mg/kg 5-HT (n 5
5) from 23 6 5% (week 0) to 272 6 8% (week 8, p ,
0.01)].
In contrast, smaller doses produced minor effects on the
epicardial coronary artery [% diameter reduction after
0.01 mg/kg acetylcholine (n 5 5) from 0 6 1% (week 0) to
2 6 2% (week 8); after 0.1 mg/kg 5-HT (n 5 5) from 0 6
2% (week 0) to 3 6 3% (week 8)], as well as on LAD blood
flow [% flow changes after 0.01 mg/kg acetylcholine (n 5 5)
from 14 6 3% (week 0) to 268 6 5% (week 8, p , 0.01);
after 0.1 mg/kg 5-HT (n 5 5) from 6 6 3% (week 0) to
210 6 4% (week 8)]. An acetylcholine dose of 0.05 mg/kg
and a 5-HT dose of 1 mg/kg were defined as suitable for
observing vascular responses in the microvascular beds
throughout the time of the experiment. All drugs were
diluted with a 0.9% NaCl solution to a volume of 1 ml, and
the same amount of 0.9% NaCl was used to flush residual
drug from the handmade Judkins-type catheter, which was
inserted from the sheath introducer. As for the change in
coronary artery diameter after treatment with vasoactive
substances, each drug was again infused into the LCA after
observing the preinjection hemodynamic state, and then
coronary angiography was performed at the time when
initial changes in coronary blood flow in response to the
vasoactive substances were maximum.
We also investigated whether an abnormality in nitric
oxide release occurs with repeated epicardial LAD endothe-
lial denudation. After 10 mg/kg Nv-nitro-L-arginine
methyl ester [L-NAME; Sigma Chemical] in 100 ml of
0.9% NaCl was administered intravenously over a period of
30 min, the same dose of acetylcholine and 5-HT was
administered into the LCA and the variables described
above were measured.
Next, balloon endothelial denudation was done just distal
to the site of the flowmeter in the LAD using a 2F Fogarty
catheter, as previously described (8). Briefly, the catheter
balloon was inflated with 0.05 ml of contrast medium and
0.05 ml of 0.9% NaCl. After balloon inflation, three
denudation procedures were performed over a length of
4 cm in the same portion of the artery. Two weeks after
denudation, we performed the same protocol as for the
examination of coronary and systemic hemodynamics, and
then the denudation protocol was done again. The hemo-
dynamic measurements and denudation procedure were
repeated every two weeks from week 0 until week 6, but the
LAD denudation was not performed in week 8. Thus, a
total of four denudations (weeks 0, 2, 4, and 6) and five
hemodynamic measurements (week 0, 2, 4, 6 and 8) were
done throughout the experimental period.
Coronary flow response to each vasoactive substance was
expressed as % change of the initial peak flow response from
the preinjection baseline value, which was nearly constant
throughout the experiment, since later on coronary flow
followed by severe flow reduction was affected by reactive
hyperemia.
Before the first epicardial LAD endothelial denudation
and at week 8, venous blood samples were taken from the
coronary sinus and the peripheral artery for measuring
platelet aggregation rate and plasma concentrations of
thromboxane B2 (TXB2) and 6-keto-PGF1a. Platelet-rich
plasma (PRP) was prepared, platelet aggregation was in-
duced with adenosine diphosphate (ADP), and collagen was
measured using the modified method of Born and Cross
(13). TXB2 and 6-keto-PGF1a concentrations in plasma
were measured with the RIA-PEG method.
At the end of the experiment, pigs were euthanized with
a lethal dose of sodium pentbarbital. For fixation of maxi-
mum vasodilated coronary arteries, the coronary arteries
were flushed with 10 ml saline containing 10 mg/kg nitro-
glycerin and 10 mg/kg adenosine after the hearts were
excised. The hearts were then perfused with 10% formal-
dehyde at a pressure of 100 mm Hg and fixed in 10%
formaldehyde for a few days. Thereafter, the hearts were cut
transversely from base to apex serially at 1-cm intervals. The
tissue was embedded in paraffin, sectioned (5 mm thick),
and stained with hematoxylin-eosin and elastica van Gieson
stains. Pictures of intramyocardial microvessels (10 to
200 mm) in the LAD perfusion areas and of the LAD
endothelial denuded portions were taken at 403 to 2003
magnification, and the parameters described later were
measured with a photomicroscope analysis system. In each
Abbreviations and Acronyms
ADP 5 adenosine diphosphate
ECG 5 electrocardiogram
ED group 5 repeated LAD endothelial denudation
group
5-HT 5 5-hydroxytryptamine
ISDN 5 isosorbide dinitrate
LAD 5 left anterior descending coronary artery
LCA 5 left coronary artery
L-NAME 5 Nv-nitro-L-arginine methyl ester
PRP 5 platelet-rich plasma
TXA2 5 thromboxane A2
TXB2 5 thromboxane B2
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heart, the lumen diameter from 10 mm to 200 mm and the
corresponding external elastic membrane cross-sectional
area to lumen cross-sectional area, which is the index of
medial thickening in various sizes of microvessels, were
measured from 6 to 30 microvessels. These values were then
averaged in every 10-mm range of lumen diameters and were
plotted (14,15). This analysis enabled us to evaluate the
vascular remodeling in different sizes of microvessels. For
the LAD endothelial denuded portion, the ratio of intima
area (mm2)-to-media area (mm2), indicating intimal thick-
ening, was also calculated to clarify the remodeling in the
repeatedly denuded portion. Histopathology and mor-
phometry were performed by investigators who were blind
to the treatment performed.
There were three groups of animals in the experiment: a
control group with flowmeter implantation without LAD
endothelial denudation (Control group, n 5 12); a group
with repeated LAD endothelial denudation every two weeks
(ED group, n 5 12); and a group with repeated LAD
denudations every two weeks, which was given 1 g/day
TXA2 synthetase inhibitor (Ozagrel hydrochloride, Ono
Ltd., Osaka, Japan) (16) and 100 mg/day aspirin (Sigma
Chemical) orally immediately after the first denudation
(Drug group, n 5 12).
Data are expressed as means 6 SEM. Serial changes of
hemodynamic variables, coronary vascular responses and
hemostatical variables prior to and following administration
of drugs were carried out using the two-way analysis of
variance (ANOVA) followed by the Scheffe´ post hoc test.
The Student t-test was used in comparing paired or un-
paired data. Differences in intimal thickening in LAD and
medial thickening corresponding to the difference in lumen
diameters in microvessels were evaluated by one-way
ANOVA followed by the Fisher exact test for multiple
comparisons. The Spearman correlation was used to inves-
tigate the relation between the vessel diameter and medial
thickening in microvessels. A level of p , 0.05 was
considered significant.
All experiments using animals were performed according
to the guidelines of Fukushima Medical University and the
Japanese Government Notification on Feeding and Safe-
keeping of Animals (No. 6).
RESULTS
Effects of repeated endothelial denudation of the epicar-
dial LAD on histopathological changes in downstream
microvessels. In the epicardial LAD denuded portion,
intimal thickening was observed in the ED group compared
to the Drug and Control groups. The intima to media ratio
at eight weeks in the ED group was 0.30 6 0.06 (sample
n 5 8, p , 0.01 vs. Drug and Control groups); in the Drug
group, 0.08 6 0.04 (sample n 5 8, p , 0.05 vs. Control
group); and in the Control group, 0.04 6 0.02 (sample n 5
8) (Fig. 1).
The mean lumen diameters of microvessels examined
were 100.1 6 5.16 mm (range 10 to 185 mm, averaged
plotted sample n 6 59, measured sample n 5 173), 98.1 6
4.56 mm (range 15 to 200 mm, averaged plotted sample n 5
69, measured sample n 5 199) and 99.3 6 5.17 mm (range
18 to 182 mm, averaged plotted sample n 5 54, measured
sample n 5 212) in the Control, ED and Drug groups,
respectively. Medial thickening in the downstream mi-
crovessels of the LAD perfusion beds in vessels with
diameters from 50 mm up to ,150 mm was greater in the
ED group (2.62 6 0.11) than in the Control (1.82 6 0.06,
p , 0.05) and Drug groups (2.11 6 0.43, p , 0.05).
However, in microvessels with diameters of ,50 mm and
Figure 1. Photomicrographs of week 8 coronary arteries stained with hematoxylin-eosin. Large epicardial coronary arteries (top) and downstream
microvascular arterioles (middle; 50 mm #lumen diameter ,150 mm; bottom; lumen diameter ,50 mm). Left panel is from the Control group, center
panel from the ED group and right panel from the Drug group. In the ED group, thickening of the media and increased perivascular fibrosis are shown.
Epicardial coronary arteries in the center and right upper panels show the denuded portions. Scale bars indicate 100 mm.
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$150 mm, medial thickening was not different among the
three groups (Figs. 1 and 2).
Baseline pressure-rate product, coronary vascular resis-
tance, and coronary diameter of the repeated denuded
portions. The baseline mean aortic pressure-rate product
and LAD vascular resistance did not change in any of the
groups (n 5 12 each) throughout the experimental time
period [pressure-rate product at week 8 (mm Hg/min):
Control group, 8164 6 425; ED group, 7992 6 438; Drug
group, 7558 6 486; vascular resistance at week 8 (mm
Hg/ml/min): Control group, 3.1 6 1.2; ED group, 2.8 6
1.1; Drug group, 2.7 6 0.9]. The baseline coronary artery
diameters before the first denudation were 2.1 6 0.2, 2.2 6
0.3 and 2.1 6 0.3 mm and at week 8 were 2.5 6 0.3, 2.4 6
0.4 and 2.5 6 0.4 mm in the Control, ED and Drug groups,
respectively.
Systemic and coronary hemodynamic responses to ace-
tylcholine, 5-HT, ISDN and adenosine. The mean aortic
pressure and heart rate after intracoronary administration of
acetylcholine, 5-HT, ISDN and adenosine did not change
in any of the groups throughout the experimental period
(data not shown).
In week 0, before epicardial LAD endothelial denuda-
tion, acetylcholine initially decreased LAD blood flow
(Control group, 214 6 5%; ED group, 215 6 4%; Drug
group, 218 6 5%), which was followed by a small increase
in flow (Control group, 21 6 6%; ED group, 22 6 5%;
Drug group, 24 6 4%) without any changes in epicardial
coronary artery diameters (Figs. 3a and 4a). Conversely, in
week 0 coronary blood flow was increased by 5-HT (Con-
trol group, 23 6 5%; ED group, 25 6 5%; Drug group,
28 6 6%) (Fig. 4b), ISDN (Control group, 94 6 12%; ED
group, 92 6 10%; Drug group, 94 6 12%) (Fig. 4c) and
adenosine (Control group, 202 6 12%; ED group, 206 6
10%; Drug group, 204 6 12%) (Fig. 4d).
The LAD flow responses to each drug did not change in
the Control group throughout the experimental period (Fig.
4). Decreased coronary blood flow response to acetylcholine
in the denuded portion in the ED group was enhanced by
repeated LAD endothelial denudation, and by week 8
acetylcholine reduced coronary blood flow to zero (p , 0.01
vs. Control group) with ECG ST-segment depression (limb
lead III, 0.24 6 0.08 mV; aVF, 0.22 6 0.06 mV; precordial
lead V5, 0.26 6 0.08 mV, p , 0.01 vs. each preinjection
state) (Figs. 3b and 4a). When LAD blood flow was
reduced to zero, a severe delay in contrast medium washout
without epicardial spasm in the repeated denuded portion
was observed in angiography (% diameter reduction, 8 6
3%) (Fig. 3b). The duration of zero coronary flow was 46 6
2.4 (38 to 57) s with the dose of acetylcholine used in this
study. This cessation of flow was followed by reactive
hyperemia (% maximal increase of flow, 214 6 28%).
Epicardial spasm by acetylcholine in the denuded portion
did not appear throughout the experiment (% diameter
reduction, 1 6 2%, 3 6 3%, 4 6 3% and 5 6 3% in weeks
0, 2, 4 and 6, respectively).
Repeated endothelial denudation also changed the effect
of 5-HT on blood flow from an increase (125 6 5%) to a
decrease with time (week 8, 220 6 4%, p , 0.05 vs.
Control group) (Fig. 4b); however, the diameter reduction
in the repeatedly denuded portion induced by 5-HT was
negligibly small in week 8 (7 6 2%) in the ED group. In
contrast, increases in coronary blood flow in response to
ISDN (week 8, 96 6 8%) and adenosine (week 8, 216 6
14%) also did not change in the ED group (Fig. 4c, d).
Decreases in coronary blood flow in response to acetyl-
choline (week 8, ED group [2100%] vs. Control group
[221 6 5%], p , 0.01) and 5-HT (week 8, ED group
[220 6 4%] vs. Control group [20 6 6%], p , 0.05) in the
ED group were prevented in the Drug group (Fig. 4a, b),
whereas coronary flow responses to ISDN and adenosine
did not differ from those of the other two groups (Fig. 4c, d).
Figure 2. Scatterplots showing the relation between the averaged values of external elastic membrane (EEM) cross-sectional area (CSA)-to-lumen CSA
ratios, and the averaged values of vessel diameter in the Control group (a), the ED group (b) and the Drug group (c). Each point in the plot represents
the average of vessels in a 10 mm range of diameters in an individual pig. In the Control and Drug groups, the ratios are relatively constant in coronary
arteries of various diameters from 10 to 200 mm, and there was no significant correlation between the averaged values of EEM CSA-to-lumen CSA ratios
and the vessel diameters. In the ED group, a significant correlation existed between the EEM CSA-to-lumen CSA ratios and the vessel diameters
(y 5 20.0001x2 1 0.0230x 1 1.6921, r2 5 0.208, p 5 0.006).
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Effects of L-NAME on acetylcholine and 5-HT re-
sponses. In all of the groups (n 5 12 each), IV adminis-
tration of 10 mg/kg L-NAME tended to increase aortic
pressure and decrease heart rate, but not significantly (data
not shown).
Pretreatment with IV L-NAME did not alter the LAD
flow response to acetylcholine in the ED group (week 0,
225 6 7% vs. 215 6 4% without L-NAME [NS]; week 6,
2100% vs. 291 6 5% without L-NAME [NS]; week 8,
2100% vs. 2100% without L-NAME [NS]). From week 2
to week 4, there also was no significant difference, although
coronary flow reduction tended to be greater in the ED
group receiving L-NAME.
Additionally, L-NAME always decreased the LAD blood
flow response to 5-HT in the ED group (week 0, 40 6 6%
vs. 25 6 5% without L-NAME [p , 0.01]; week 8, 278 6
6% vs. 220 6 4% without L-NAME [p , 0.01]). However,
as mentioned above, the coronary flow-reducing effect of
L-NAME on 5-HT responses did not change throughout
the experimental period (week 0, D65 6 7% [from 25 6 5%
to 240 6 6%]; week 8, D58 6 8% [from 220 6 4% to
278 6 6%]; NS).
The effects of L-NAME on acetylcholine and 5-HT-
induced LAD flow responses in the Control group and the
Drug group were similar to those of the ED group, and
consequently there was no significant effect of L-NAME on
the coronary flow responses to acetylcholine or 5-HT in any
of the three experimental groups. The differences between
groups in response to acetylcholine and 5-HT were pre-
served, regardless of treatment with L-NAME.
Hemostasis analysis. In the Control group (n 5 12),
plasma concentrations of 6-keto-PGF1a, and TXB2 in
coronary sinus blood did not change throughout the exper-
imental period (6-keto-PGF1a, 66.8 6 5.6 pg/ml [week 0]
to 72.2 6 6.8 pg/ml [week 8]; TXB2, 118 6 13.4 pg/ml
[week 0] to 142 6 10.6 pg/ml [week 8]). However, the
plasma concentration of 6-keto-PGF1a in coronary sinus
blood decreased in the repeated LAD endothelial denuda-
tion group irrespective of drug administration (ED group
[n 5 12]: from 64.8 6 4.9 pg/ml [week 0] to 40.4 6
5.2 pg/ml [week 8], p , 0.05 vs. Control group; Drug group
[n 5 12]: from 69.5 6 5.2 pg/ml to 42.6 6 5.8 pg/ml, p ,
0.05 vs. Control group). Moreover, the plasma concentra-
tion of TXB2 in coronary sinus blood increased in the
ED group (from 108 6 12.8 pg/ml [week 0] to 309 6
23.4 pg/ml [week 8], p , 0.01 vs. Control group) but
decreased in the Drug group (from 115 6 11.2 pg/ml [week
0] to 22 6 4.2 pg/ml [week 8], p , 0.01 vs. Control and
ED groups).
Adenosine diphosphate and collagen-induced PRP ag-
gregation rates in the Control group (n 5 12) did not
change in coronary sinus blood or in peripheral arterial
blood (coronary sinus blood; ADP, 36 6 5% to 42 6 5%;
collagen, 28 6 6% to 32 6 6%; peripheral arterial blood;
ADP; 35 6 4% to 40 6 6%; collagen, 26 6 4% to 30 6 5%,
week 0 to 8, respectively). In the ED group (n 5 12), ADP
and collagen-induced PRP aggregation rates were increased
in coronary sinus blood (ADP, from 36 6 4% [week 0] to
88 6 6% [week 8], p , 0.01 vs. Control group; collagen,
from 25 6 5% [week 0] to 72 6 8% [week 8], p , 0.05 vs.
Figure 3. Representative tracings and coronary angiograms from a pig in the ED group at (a) week 0 (before endothelial denudation) and (b) week 8 (2
weeks after four denudations). Coronary blood flow at week 8 initially decreased to zero flow, and subsequent reactive hyperemia appeared with ECG ST
depression in limb lead III after intracoronary administration of 0.05 mg/kg acetylcholine (ACh) without showing epicardial coronary artery
vasoconstriction. BP 5 aortic blood pressure; CBF 5 coronary blood flow in LAD; ECG 5 electrocardiogram.
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Control group]; however, they did not change in peripheral
arterial blood (ADP, 35 6 5% [week 0] to 48 6 7% [week
8]; collagen, 26 6 6% [week 0] to 39 6 5% [week 8]).
In the Drug group (n 5 12), ADP and collagen-induced
PRP aggregation rates were decreased in coronary sinus
blood (ADP, from 38 6 6% [week 0] to 6 6 2% [week 8];
collagen, from 29 6 5% [week 0] to 4 6 2% [week 8]; p ,
0.05 vs. Control and p , 0.01 vs. ED group) and in
peripheral arterial blood (ADP, from 36 6 6% [week 0] to
4 6 3% [week 8]; collagen; from 27 6 6% [week 0] to 3 6
3% [week 8], p , 0.05 vs. Control and ED groups).
DISCUSSION
Epicardial coronary artery endothelial injury and micro-
vascular spasm with remodeling. Recently, according to
Wiedermann et al. (17), small-vessel disease is frequently
observed by intravascular ultrasound in patients showing
abnormal epicardial vessels (plaque or intimal thickening)
who have entirely normal coronary angiograms. However, a
causal relationship between epicardial coronary artery and
downstream microvascular abnormalities has not been es-
tablished. Moreover, despite clinical observation (9) it
remains unclear whether small but additional narrowing of
the epicardial stenosed coronary artery plays a role in
microvascular spasm with ECG ST change and lactate
production in coronary sinus blood in the human, and it also
remains unclear how coronary flow actually decreases in a
microvessel anginal attack.
In the present study we showed that, in a pig model of
coronary microvascular spasm showing transient coronary
zero flow by administration of acetylcholine, the abnormal
microvascular flow response is accompanied by microvascu-
lar remodeling similar to that in the human (2,4,18). As far
as we know, this is the first demonstration that coronary
flow in a downstream perfusion bed perfused by a repeatedly
denuded epicardial coronary artery stops briefly after acetyl-
choline injection and is accompanied by ischemic ECG ST
changes but not epicardial coronary spasm. Coronary mi-
crovascular remodeling in this model, which was induced by
upstream repeated coronary artery endothelial injury, oc-
curred especially in smaller microvessels (50 to 150 mm).
The reason for this is unclear, but it may have been related
to altered expression of platelet-derived growth factors in
the coronary microcirculation.
Therefore, to better understand the mechanisms of the
microvascular remodeling process or the different responses
(depending on the diameter of small vessels) to repeated
epicardial coronary artery endothelial denudation, the
transmyocardial production of platelet-derived growth fac-
tors should be measured. Another important issue to be
clarified is where the spastic site resides in microvessels in
the zero flow state. In particular, no information is presently
Figure 4. Time-related percent changes in LAD blood flow from the baseline state in response to various vasoactive agents: (a) acetylcholine, 0.05 mg/kg;
(b) 5-HT, 1 mg/kg; (c) ISDN, 10 mg/kg; (d) adenosine, 10 mg/kg. Control group (x); ED group (open circle); and Drug group (closed circle) (n 5 12,
each). Values are means 6 SEM. ¥p , 0.01 by two-way ANOVA. †p , 0.01 vs. 0 week at the same portion in the same condition. §p , 0.01 vs. two
weeks at the same portion in the same condition. @p , 0.01 vs. the Control group in the same experimental period. ¶p , 0.01 vs. the Drug group in the
same experimental period.
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available as to how microvessel morphological changes
relate to functional flow alterations in response to drugs.
Thromboxane A2 and coronary microvascular remodel-
ing. Epicardial coronary artery endothelial injury is likely to
occur repeatedly during a lifetime as a result of local shear
forces and/or various risk factors. An injured surface of
endothelium activates platelets (9). Activated platelets re-
lease several vasoconstrictive substances, such as 5-HT,
TXA2, ADP and thrombin, that are also major contributors
to vascular smooth muscle cell migration (10,19). In addi-
tion, endothelial injury mimics inflammatory changes, in
which infiltration of neutrophils and macrophages into the
vessel is likely to occur and in which TXA2 is considered to
be released from endothelial cells through the action of
Cox-2 (20). Thromboxane A2 markedly enhances
thrombin-induced proliferation of vascular smooth muscle
cells (21).
Moreover, according to our results, TXA2 also seems to
be an important factor in microvascular remodeling because
a TXA2 synthetase inhibitor and aspirin prevented micro-
vascular remodeling. However, we did not examine the
effect of TXA2 synthetase inhibitor alone. Additionally, it is
plausible that a decrease in the production of a prostacyclin
(6-keto-PGF1a) associated with repeated epicardial coro-
nary artery denudation might be a cofactor for promoting
abnormal structural and functional changes in the micro-
vasculature. Thus, further study is needed to clarify how the
combined effects of TXA2 synthetase inhibitor and aspirin
differ from treatment with each drug alone on the micro-
vascular remodeling process and/or spasm induction.
Nitric oxide and microvascular spasm. Although pre-
treatment with IV L-NAME affected baseline coronary flow
rate in each group, it did not affect the LAD flow response
to acetylcholine and 5-HT throughout the experimental
period. Therefore, it seems unlikely that an abnormality in
nitric oxide release from the microvascular endothelium per
se contributed to the prominent flow reduction following
each drug administration at the later stages of the repeated
denuding procedures.
Study limitations. First, platelet deposition at the site of
endothelial injury was not consecutively determined after
endothelial injury; however, in our model, regenerated
endothelial cells covered the injured surface two weeks after
injury without the formation of large thrombi (8). Accord-
ing to Yan et al. (9), de-endothelialization resulted in the
immediate adhesion of platelets to the injured vessel wall;
but large thrombi were not formed, and the platelets
disappeared from the injured surface within a few days.
Second, although our animal microvessel disease model is
similar to morphological changes in microvessel or the
vasoconstrictive responses including ECG ST changes to
various cardiovascular drugs in humans (22), spontaneous
microvascular spasm attacks were not observed. Third, we
did not quantitatively estimate regional wall-motion abnor-
malities during attacks of microvascular spasm. It has been
reported that long-lasting microvascular abnormalities, in-
cluding spasm, may lead to myocardial ischemia in human
diabetes mellitus and in an animal cardiomyopathy model
(23,24). However, there are little data showing wall-motion
abnormality during an attack of coronary microvascular
spasm, although an ischemic cause of syndrome X is a
hypothesis that has been abandoned by some of its initial
proponents (25). With our model in only a few cases
examined during the coronary flow cessation state with
echocardiography, it was evident that the altered microvas-
cular flow responses resulted in significant regional myocar-
dial dysfunction of even a transient nature. However, the
data are sparse and premature and further study is needed to
clarify this issue.
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